Biological E. to begin Phase III trial of COVID-19 vaccine Reuters May 8, 2021 The company plans to produce 75 million to 80 million doses a month from August
Biological E signs tech transfer pacts with Baylor College of Medicine and J&J for COVID-19… EP News Bureau Aug 14, 2020 The agreements are for Baylor's recombinant protein vaccine candidate and J&J's Ad26.COV2.S vaccine, currently in Phase 1/2…
Merck and Baylor College of Medicine sign agreement for R&D in neglected diseases EP News Bureau Aug 10, 2017 The collaboration includes training and exchange of technical know-how in process development and formulation, filling knowledge…
